FARALLON CAPITAL MANAGEMENT LLC - THERAVANCE BIOPHARMA INC ownership

THERAVANCE BIOPHARMA INC's ticker is and the CUSIP is 88339KAA0. A total of 20 filers reported holding THERAVANCE BIOPHARMA INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
FARALLON CAPITAL MANAGEMENT LLC ownership history of THERAVANCE BIOPHARMA INC
ValueSharesWeighting
Q2 2021$54,114,000
-6.6%
56,695,0000.0%0.22%
-23.3%
Q1 2021$57,933,000
+7.7%
56,695,0000.0%0.29%
-11.1%
Q4 2020$53,806,000
+8.0%
56,695,0000.0%0.32%
-6.1%
Q3 2020$49,808,000
+21.9%
56,695,000
+35.3%
0.34%
+5.5%
Q2 2020$40,869,000
+160.6%
41,905,000
+156.1%
0.33%
+142.2%
Q1 2020$15,685,00016,360,0000.14%
Other shareholders
THERAVANCE BIOPHARMA INC shareholders Q4 2020
NameSharesValueWeighting ↓
Context Capital Management, LLC 13,473,000$12,756,0001.74%
Shaolin Capital Management LLC 14,065,000$13,281,0000.93%
ZAZOVE ASSOCIATES LLC 3,773,000$3,584,0000.44%
FARALLON CAPITAL MANAGEMENT LLC 56,695,000$53,806,0000.32%
Baupost Group 30,000,000$28,396,0000.26%
Aequim Alternative Investments LP 3,000,000$2,840,0000.21%
WOLVERINE ASSET MANAGEMENT LLC 24,100,000$22,817,0000.17%
TENOR CAPITAL MANAGEMENT Co., L.P. 5,500,000$5,257,0000.15%
SSI INVESTMENT MANAGEMENT LLC 1,750,000$1,648,0000.12%
GABELLI & Co INVESTMENT ADVISERS, INC. 430,000$406,0000.06%
View complete list of THERAVANCE BIOPHARMA INC shareholders